Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050661 · ClinicalTrials.gov registry record · Phase 1
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00050661: Completed Phase 1 study, sponsored by Rockefeller University.
NCT00050661 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050661, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.
Interventions
- DRUG Daclizumab
- DEVICE NB-UVB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 1997-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
What the finished NCT00050661 record still lists
NCT00050661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Daclizumab is the first listed.
NCT00050661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050661 about?
NCT00050661 is a clinical study titled "To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris". This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.
What is the current status of trial NCT00050661?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 1997-10. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00050661?
The interventions under investigation include: Daclizumab (DRUG), NB-UVB (DEVICE).
Who is sponsoring clinical trial NCT00050661?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00050661's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia